Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lundbeck receives FDA Complete Response Letter on Serdolect for the treatment of schizophrenia
Lundbeck, 06/26/09

H. Lundbeck A/S announced today that the company has received a Complete Response Letter from the US Food and Drug Administration for Serdolect for the treatment of schizophrenia. The Agency's complete response included request for additional data to best understand the appropriate patient population for which Serdolect could be made available. Lundbeck is currently evaluating the feedback from FDA and will work with the Agency to resolve these outstanding questions and discuss appropriate next steps required to bring Serdolect safely to market.


Today in Regulatory Issues...keeping you current

Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09

See All of Regulatory Issues

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address